Ensitrelvir Fumaric Acid in Patients with COVID-19 Retrospective Chart Review - Kimoto Internal Medicine Clinic
Not Applicable
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000051462
- Lead Sponsor
- Shionogi & Co., Ltd.
- Brief Summary
The study enrolled 32 people, and the main COVID-19 symptoms included sore throat in 22 patients and fever in 21 patients. No sore throat was observed 7 days after the start of administration. Fever and cough decreased to 8 and 3 patients on the second day, and no fever was confirmed on the seventh day. Two patients reported nausea as a side effect of ensitrevir, but both were mild.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who meet any of the following criteria are excluded from the study. 1) Patients who were treated off-label 2) Patients who refuse to participate in this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method